As Pfizer continues its attempts for a takeover of AstraZeneca (LSE: AZN) (NYSE: AZN.US), Motley Fool managing director Jill Ralph and senior analyst Nate Weisshaar discuss what might be best for shareholders in the British pharmaceutical firm…
https://www.youtube.com/watch?v=T7rAMcP-vPM